Success Metrics

Active Trials
3(75%)

Phase Distribution

Ph phase_1
1
25%
Ph phase_3
2
50%
Ph phase_2
1
25%

Phase Distribution

1

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
2(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

4

all time

Status Distribution
Active(4)

Detailed Status

Recruiting2
Active, not recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
3
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 32 (50.0%)

Trials by Status

recruiting250%
active_not_recruiting125%
not_yet_recruiting125%

Recent Activity

3 active trials
Showing 4 of 4
recruitingphase_3

Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer

NCT06712472
recruitingphase_2

Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment

NCT02029001
not_yet_recruitingphase_1

Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer

NCT07090369
active_not_recruitingphase_3

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

NCT04624204

Clinical Trials (4)

Showing 4 of 4 trials
NCT06712472Phase 3

Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer

Recruiting
NCT02029001Phase 2

Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment

Recruiting
NCT07090369Phase 1

Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer

Not Yet Recruiting
NCT04624204Phase 3

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

Active Not Recruiting

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4